ACET (Adicet Bio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ACET officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Lloyd Klickstein | Chief Medical Officer | A | — | — |
| 2026-08-07 | Lloyd Klickstein | Chief Medical Officer | A | — | — |
| 2026-06-23 | Lloyd Klickstein | Director | A | — | — |
| 2026-06-23 | Blake Aftab | Chief Scientific Officer | A | — | — |
| 2026-06-23 | Andrew Sinclair | Director | A | — | — |
| 2026-06-23 | Katie Peng | Director | A | — | — |
| 2026-06-23 | Jeffrey Chodakewitz | Director | A | — | — |
| 2026-06-23 | Michael Grissinger | Director | A | — | — |
| 2026-06-23 | Chen Schor | President & CEO | A | — | — |
| 2026-06-23 | STEVE DUBIN | Director | A | — | — |
| 2026-04-29 | Rajeev M. Shah | 10%+ Owner | J | — | — |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | Buy | — | — |
| 2026-04-09 | OrbiMed Israel GP Ltd. | 10%+ Owner | Sell | — | — |
| 2026-03-27 | Brian Nicholas Harvey | Chief Financial Officer | A | — | — |
| 2026-03-27 | Chen Schor | President & CEO | A | — | — |
| 2026-03-27 | Julia D. Maltzman | Chief Medical Officer | A | — | — |
| 2026-03-27 | Don Healey | Chief Technology Officer | A | — | — |
| 2026-03-27 | Blake Aftab | Chief Scientific Officer | A | — | — |
| 2026-01-27 | Brian Nicholas Harvey | Chief Financial Officer | F | — | — |
| 2026-01-27 | Don Healey | Chief Technology Officer | F | — | — |
| 2026-01-27 | Chen Schor | President & CEO | F | — | — |
| 2026-01-27 | Blake Aftab | Chief Scientific Officer | F | — | — |
| 2025-10-10 | OrbiMed Israel BioFund GP Limited Partnership | 10%+ Owner | Buy | — | — |
| 2025-06-13 | Jeffrey Chodakewitz | Director | A | — | — |
| 2025-06-13 | Andrew Sinclair | Director | A | — | — |
| 2025-06-13 | Katie Peng | Director | A | — | — |
| 2025-06-13 | STEVE DUBIN | Director | A | — | — |
| 2025-06-13 | Lloyd Klickstein | Director | A | — | — |
| 2025-04-21 | Michael Grissinger | Director | A | — | — |
| 2025-02-04 | Don Healey | Chief Technology Officer | A | — | — |
| 2025-02-04 | Julia D. Maltzman | Chief Medical Officer | A | — | — |
| 2025-02-04 | Chen Schor | President & CEO | A | — | — |
| 2025-02-04 | Blake Aftab | Chief Scientific Officer | A | — | — |
| 2025-02-04 | Brian Nicholas Harvey | Chief Financial Officer | A | — | — |
| 2025-01-28 | Brian Nicholas Harvey | Chief Financial Officer | F | — | — |
| 2025-01-28 | Blake Aftab | Chief Scientific Officer | F | — | — |
| 2025-01-28 | Chen Schor | President & CEO | F | — | — |
| 2025-01-28 | Don Healey | Chief Technology Officer | F | — | — |
| 2024-06-07 | Katie Peng | Director | A | — | — |
| 2024-06-07 | Don Healey | Chief Technology Officer | A | — | — |
| 2024-06-07 | Jeffrey Chodakewitz | Director | A | — | — |
| 2024-06-07 | Chen Schor | President & CEO | A | — | — |
| 2024-06-07 | Blake Aftab | Chief Scientific Officer | A | — | — |
| 2024-06-07 | Francesco Galimi | SVP & Chief Medical Officer | A | — | — |
| 2024-06-07 | Aya Jakobovits | Director | A | — | — |
| 2024-06-07 | STEVE DUBIN | Director | A | — | — |
| 2024-06-07 | Brian Nicholas Harvey | Chief Financial Officer | A | — | — |
| 2024-06-07 | CARL L GORDON | Director | A | — | — |
| 2024-06-07 | Michael Kauffman | Director | MIXED | — | — |
| 2024-06-07 | Andrew Sinclair | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,033,605 | — |
| — | 10%+ Owner | 932,624 | — |
| — | Director | 133,318 | — |
| — | Director | 78,499 | — |
| — | Director | 69,029 | — |
| — | Director | 61,891 | — |
| — | Director | 56,430 | — |
| — | Director | 43,128 | — |
| — | Director | 41,154 | — |
| — | Director | 40,416 | — |
| — | President & CEO | 9,536 | — |
| — | Director | 9,368 | — |
| — | Chief Medical Officer | 6,785 | — |
| — | SVP & Chief Medical Officer | 6,363 | — |
| — | Chief Financial Officer | 5,145 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACET quote page; the site-wide leaderboard is on the insider transactions hub.